• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.

作者信息

Repetto Federica, Burzi Lorenza, Ribero Simone, Quaglino Pietro, Dapavo Paolo

机构信息

Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.

出版信息

Acta Derm Venereol. 2022 Sep 28;102:adv00780. doi: 10.2340/actadv.v102.2926.

DOI:10.2340/actadv.v102.2926
PMID:35971829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9677263/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8044/9677263/c68e9621a2b2/ActaDV-102-2926-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8044/9677263/c68e9621a2b2/ActaDV-102-2926-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8044/9677263/c68e9621a2b2/ActaDV-102-2926-g001.jpg

相似文献

1
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.司库奇尤单抗治疗化脓性汗腺炎的疗效和安全性：病例系列
Acta Derm Venereol. 2022 Sep 28;102:adv00780. doi: 10.2340/actadv.v102.2926.
2
Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures.在抗TNF和抗白细胞介素-17治疗失败后，司库奇尤单抗对一例顽固性化脓性汗腺炎的疗效。
Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.
3
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.用阿达木单抗治疗重度顽固性化脓性汗腺炎。
J Dtsch Dermatol Ges. 2009 Feb;7(2):139-41. doi: 10.1111/j.1610-0387.2008.06918.x.
4
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.每4周使用100毫克古塞库单抗治疗化脓性汗腺炎患者及文献综述
Dermatol Ther. 2020 May;33(3):e13456. doi: 10.1111/dth.13456. Epub 2020 May 3.
5
Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
Indian J Dermatol Venereol Leprol. 2017 Sep-Oct;83(5):615-617. doi: 10.4103/ijdvl.IJDVL_147_16.
6
A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab.一例用司库奇尤单抗成功治疗的中度化脓性汗腺炎和银屑病病例。
Int J Dermatol. 2022 Apr;61(4):e126-e129. doi: 10.1111/ijd.15704. Epub 2021 Jun 20.
7
Infliximab for the treatment of hidradenitis suppurativa.英夫利昔单抗治疗化脓性汗腺炎。
J Am Acad Dermatol. 2003 Nov;49(5 Suppl):S275-6. doi: 10.1016/s0190-9622(03)01132-0.
8
The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.前沿。用阿达木单抗治疗重度化脓性汗腺炎。
Arch Dermatol. 2006 Sep;142(9):1110-2. doi: 10.1001/archderm.142.9.1110.
9
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.抗肿瘤坏死因子α治疗失败后，使用司库奇尤单抗成功治疗顽固性化脓性汗腺炎。
Br J Dermatol. 2021 May;184(5):966-967. doi: 10.1111/bjd.19716. Epub 2021 Feb 1.
10
Infliximab for the treatment of hidradenitis suppurativa.英夫利昔单抗治疗化脓性汗腺炎。
Dermatology. 2007;215(1):41-4. doi: 10.1159/000102032.

引用本文的文献

1
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study.抗白细胞介素-17/23药物治疗合并银屑病的中重度化脓性汗腺炎：一项多中心回顾性研究
Dermatol Pract Concept. 2024 Oct 30;14(4):e2024250. doi: 10.5826/dpc.1404a250.
2
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
3
Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives.

本文引用的文献

1
Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.化脓性汗腺炎：宿主-微生物与免疫发病机制是重要的未来研究方向的基础。
JID Innov. 2021 Jan 12;1(1):100001. doi: 10.1016/j.xjidi.2021.100001. eCollection 2021 Mar.
2
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
3
Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures.
化脓性汗腺炎要点：诊断与治疗观点的全面综述
Ann Med Surg (Lond). 2024 Jul 1;86(9):5304-5313. doi: 10.1097/MS9.0000000000002345. eCollection 2024 Sep.
4
Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports.用司库奇尤单抗治疗头皮难治性蜂窝织炎：2例病例报告
JAAD Case Rep. 2023 Oct 29;42:87-90. doi: 10.1016/j.jdcr.2023.10.011. eCollection 2023 Dec.
5
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
6
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
7
The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review.化脓性汗腺炎的当前临床试验概况：一项叙述性综述
Dermatol Ther (Heidelb). 2023 Jul;13(7):1391-1407. doi: 10.1007/s13555-023-00935-x. Epub 2023 Jun 1.
8
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
9
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.阿达木单抗治疗化脓性汗腺炎失败后抗白细胞介素-17和白细胞介素-23药物的疗效：一项试点研究
Acta Derm Venereol. 2023 Apr 19;103:adv5278. doi: 10.2340/actadv.v103.5278.
在抗TNF和抗白细胞介素-17治疗失败后，司库奇尤单抗对一例顽固性化脓性汗腺炎的疗效。
Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.
4
A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab.一例用司库奇尤单抗成功治疗的中度化脓性汗腺炎和银屑病病例。
Int J Dermatol. 2022 Apr;61(4):e126-e129. doi: 10.1111/ijd.15704. Epub 2021 Jun 20.
5
Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?古塞库单抗在重度化脓性汗腺炎治疗中有望发挥作用？
Dermatol Ther. 2021 May;34(3):e14930. doi: 10.1111/dth.14930. Epub 2021 Mar 14.
6
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.抗肿瘤坏死因子α治疗失败后，使用司库奇尤单抗成功治疗顽固性化脓性汗腺炎。
Br J Dermatol. 2021 May;184(5):966-967. doi: 10.1111/bjd.19716. Epub 2021 Feb 1.
7
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.每4周使用100毫克古塞库单抗治疗化脓性汗腺炎患者及文献综述
Dermatol Ther. 2020 May;33(3):e13456. doi: 10.1111/dth.13456. Epub 2020 May 3.
8
Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review.乌司奴单抗治疗化脓性汗腺炎患者：多中心病例系列和系统评价。
J Dermatolog Treat. 2022 Feb;33(1):348-353. doi: 10.1080/09546634.2020.1755008. Epub 2020 Apr 21.
9
Guselkumab in the treatment of severe hidradenitis suppurativa.古塞库单抗治疗重度化脓性汗腺炎
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e140-e141. doi: 10.1111/jdv.15368. Epub 2019 Feb 18.
10
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.阿达木单抗治疗化脓性汗腺炎的两项 3 期临床试验。
N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.